[How I Manage B Cell Lymphoma Patients Treated with CD19 Specific CAR-T Cell Throughout Whole-process Management]

Overview

Journal Zhonghua Xue Ye Xue Za Zhi

Specialty Hematology

Date 2022 Apr 11

PMID 35405776

Authors

W B Qian

H Liu

Affiliations

Soon will be listed here.

Citing Articles

2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.

Li P, Liu Y, Liang Y, Bo J, Gao S, Hu Y Cancer Biol Med. 2023; 20(2).

PMID: 36861439 PMC: 9978889. DOI: 10.20892/j.issn.2095-3941.2022.0585.

References

Fraietta J, Beckwith K, Patel P, Ruella M, Zheng Z, Barrett D . Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016; 127(9):1117-27. PMC: 4778162. DOI: 10.1182/blood-2015-11-679134. View

Abramson J, Palomba M, Gordon L, Lunning M, Wang M, Arnason J . Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852. DOI: 10.1016/S0140-6736(20)31366-0. View

Nastoupil L, Jain M, Feng L, Spiegel J, Ghobadi A, Lin Y . Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2020; 38(27):3119-3128. PMC: 7499611. DOI: 10.1200/JCO.19.02104. View

Wei J, Liu Y, Wang C, Zhang Y, Tong C, Dai G . The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. Signal Transduct Target Ther. 2020; 5(1):134. PMC: 7388484. DOI: 10.1038/s41392-020-00256-x. View

Locke F, Ghobadi A, Jacobson C, Miklos D, Lekakis L, Oluwole O . Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2018; 20(1):31-42. PMC: 6733402. DOI: 10.1016/S1470-2045(18)30864-7. View

Gaut D, Tang K, Sim M, Duong T, Young P, Sasine J . Filgrastim associations with CAR T-cell therapy. Int J Cancer. 2020; 148(5):1192-1196. PMC: 7894177. DOI: 10.1002/ijc.33356. View

Schuster S, Bishop M, Tam C, Waller E, Borchmann P, McGuirk J . Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018; 380(1):45-56. DOI: 10.1056/NEJMoa1804980. View

Neelapu S, Locke F, Bartlett N, Lekakis L, Miklos D, Jacobson C . Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017; 377(26):2531-2544. PMC: 5882485. DOI: 10.1056/NEJMoa1707447. View

Krammer P . CD95's deadly mission in the immune system. Nature. 2000; 407(6805):789-95. DOI: 10.1038/35037728. View

10.

Yang C, Xie M, Zhang K, Liu H, Liang A, Young K . Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection. Leukemia. 2020; 34(11):3055-3059. DOI: 10.1038/s41375-020-0913-y. View

11.

Lee D, Gardner R, Porter D, Louis C, Ahmed N, Jensen M . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95. PMC: 4093680. DOI: 10.1182/blood-2014-05-552729. View

12.

Ying Z, Yang H, Guo Y, Li W, Zou D, Zhou D . Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China. Cancer Med. 2020; 10(3):999-1011. PMC: 7897944. DOI: 10.1002/cam4.3686. View

13.

Liang Y, Liu H, Lu Z, Lei W, Zhang C, Li P . CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies. J Hematol Oncol. 2021; 14(1):26. PMC: 7885572. DOI: 10.1186/s13045-021-01044-y. View

14.

Hill J, Li D, Hay K, Green M, Cherian S, Chen X . Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2017; 131(1):121-130. PMC: 5755046. DOI: 10.1182/blood-2017-07-793760. View

15.

Galli E, Allain V, Di Blasi R, Bernard S, Vercellino L, Morin F . G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma. Bone Marrow Transplant. 2020; 55(12):2347-2349. DOI: 10.1038/s41409-020-01006-x. View

16.

Liu H, Li P, Zhao A, Lei W, Liang A, Qian W . Incidence and prophylaxis of herpes zoster in relapsed or refractory B-cell lymphoma patients after CD19-specific CAR-T cell therapy. Leuk Lymphoma. 2021; 63(4):1001-1004. DOI: 10.1080/10428194.2021.2010062. View

17.

Vitale C, Strati P . CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences. Front Oncol. 2020; 10:849. PMC: 7326110. DOI: 10.3389/fonc.2020.00849. View

18.

Lee D, Santomasso B, Locke F, Ghobadi A, Turtle C, Brudno J . ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2018; 25(4):625-638. DOI: 10.1016/j.bbmt.2018.12.758. View

19.

Hayden P, Roddie C, Bader P, Basak G, Bonig H, Bonini C . Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European.... Ann Oncol. 2021; 33(3):259-275. DOI: 10.1016/j.annonc.2021.12.003. View